Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Personalization of Cancer Treatment: Exploring the Role of Chronotherapy in Immune Checkpoint Inhibitor Efficacy

Cancers(2025)10.3390/cancers17050732Source: DataRank Database

Personalization of Cancer Treatment: Exploring the Role of Chronotherapy in Immune Checkpoint Inhibitor Efficacy is a research paper published in Cancers (2025). On theSindex it has a DataRank of 0. It has been cited 16 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access16 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)OA: goldTopics (13)IDs (PubMed, PMC)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Avery Billo,Terri Clister ORCID,K Doan ORCID,Elizabeth Berry ORCID,Deanne Tibbitts ORCID

Live enrichment

PubMed:40075580 PMC:PMC11899640

National Institutes of Health

Grant: 1R01DE033038

National Institutes of Health

Grant: K12AR084221

NICHD NIH HHS

Grant: K12 HD043488

National Institutes of Health

Grant: I01CX002750

NIDCR NIH HHS

Grant: R01 DE033038

National Institutes of Health

Grant: 1R01DE033038-01A1

Identifying and modulating pathologic T cells that govern oral mucosal immune related adverse events from immune checkpoint blockade

National Institutes of Health

Grant: 1I01CX002750-01A2

Mechanistic Assessment and Treatment of Immune Related Adverse Events

National Institutes of Health

Grant: 8K12AR084221-23

Oregon BIRCWH: Scholars in Women's Health Research Across the Lifespan

goldLicense: cc-by

publisherhttps://doi.org/10.3390/cancers17050732

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11899640

Europe_PMChttps://europepmc.org/articles/PMC11899640

Europe_PMChttps://europepmc.org/articles/PMC11899640?pdf=render

https://pubmed.ncbi.nlm.nih.gov/40075580

Fields of Study

03 medical and health sciences0302 clinical medicine

Keywords

CancerImmunotherapyCircadian rhythmsSide effectsSex differencesChronotherapyImmune-related Adverse EventsImmune Checkpoint InhibitorInfusion TimingTime-of-day AdministrationReview